Combination therapy for acute myocardial infarction: Glycoprotein ilb/iiia inhibitors plus thrombolysis
Key result
Combining glycoprotein IIb/IIIa receptor inhibition with reduced-dose thrombolytic therapy improves early infarct-related artery patency without increasing bleeding risk in acute MI.
Why the study?
Does combining GP IIb/IIIa receptor inhibitors with reduced-dose thrombolytic therapy improve early infarct-related artery patency without increasing bleeding risk in patients with acute ST-segment elevation MI?
Population
Patients with acute ST-segment elevation myocardial infarction (MI)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports evaluation of combination regimens in STEMI; leaves open outcome benefits versus contemporary reperfusion.
Structured PICO
Does combining GP IIb/IIIa receptor inhibitors with reduced-dose thrombolytic therapy improve early infarct-related artery patency without increasing bleeding risk in patients with acute ST-segment elevation MI?
P
Population
Patients with acute ST-segment elevation myocardial infarction (MI)
I
Intervention
Glycoprotein (GP) IIb/IIIa receptor inhibitors combined with reduced-dose thrombolytic therapy
O
Outcome
Early infarct-related artery patencysurrogate
Combining GP IIb/IIIa inhibitors with reduced-dose thrombolytics shows physiologic and clinical promise for improving early artery patency in STEMI.
Cite This Study
Christopher P. Cannon (1999) conducted a review in acute ST-segment elevation myocardial infarction (MI). Glycoprotein IIb/IIIa receptor inhibitors combined with reduced-dose thrombolytic agents was evaluated on early infarct-related artery patency. Combining glycoprotein IIb/IIIa receptor inhibition with reduced-dose thrombolytic therapy improves early infarct-related artery patency without increasing bleeding risk in acute MI.